{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:47:25Z","timestamp":1782841645363,"version":"3.54.5"},"reference-count":28,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Prophylaxis for chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) is essential. Four-drug antiemetic therapy, consisting of a neurokinin-1 receptor antagonist (NK1RA), a 5-hydroxytryptamine type 3 receptor antagonist (5-HT3RA), dexamethasone (DEX), and olanzapine (OLZ), is currently recommended for HEC. However, the efficacy, optimal dosing schedule, and appropriate dosage of OLZ remain unclear when combined with a highly selective NK1RA, fosnetupitant (FosNTP).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aimed to evaluate the efficacy and safety of a four-drug antiemetic regimen including FosNTP and OLZ for prophylaxis of CINV in patients receiving anthracycline-based (neo)adjuvant chemotherapy for early breast cancer (EBC) and to explore outcomes with OLZ dose adjustments in the second cycle.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This single-institution, prospective observational study will enroll 100 patients with EBC who undergo HEC. All patients will receive a four-drug antiemetic regimen consisting of FosNTP, 5-HT3RA, DEX, and the guideline-recommended dose of OLZ administered orally from days \u20131 to 4. During the second cycle of treatment, OLZ dosing may be adjusted based on tolerability and patient preference. The primary endpoint is the proportion of patients who experienced no nausea during the overall phase (0\u2010120 h) of the first cycle, as assessed using the daily visual analog scale. A sample size of 86 was calculated to assess the efficacy of the four-drug antiemetic regimen, including OLZ, assuming an expected no nausea rate of 42%, a threshold no nausea rate of 27% based on historical data, 90% power, and a 1-sided significance level of 5.0%. A single-sample z-test with a normal approximation will be used for the analyses.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study was approved by the Ethics Committee of the National Hospital Organization Kyushu Cancer Center, and participant recruitment and data collection commenced in May 2024. As of September 2025, approximately 70 participants have been recruited. Data collection is expected to continue until April 2026, and both data collection and analyses are anticipated to be completed in 2027.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This study will provide real-world evidence on the effectiveness and safety of a four-drug antiemetic regimen, including FosNTP and OLZ, in patients receiving anthracycline-based HEC and may inform optimal OLZ dosing strategies.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/85648","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:15:08Z","timestamp":1767132908000},"page":"e85648-e85648","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Antiemetic Support in Anthracycline-Based Chemotherapy for Early Breast Cancer: Protocol for a Prospective Observational Study of Four-Drug Antiemetic Therapy Including Fosnetupitant and Olanzapine"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2612-0769","authenticated-orcid":false,"given":"Ayako","family":"Higuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0265-9231","authenticated-orcid":false,"given":"Yumiko","family":"Koi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2028-1476","authenticated-orcid":false,"given":"Tomoaki","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6383-5461","authenticated-orcid":false,"given":"Yuka","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8709-4031","authenticated-orcid":false,"given":"Wakako","family":"Tajiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9844-5107","authenticated-orcid":false,"given":"Junji","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1237-5366","authenticated-orcid":false,"given":"Sayuri","family":"Akiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9378-1915","authenticated-orcid":false,"given":"Hideki","family":"Ijichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2694-2901","authenticated-orcid":false,"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1551-8189","authenticated-orcid":false,"given":"Chinami","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8140-4565","authenticated-orcid":false,"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0577-6203","authenticated-orcid":false,"given":"Hiroaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7108-6103","authenticated-orcid":false,"given":"Toshihiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1640-5315","authenticated-orcid":false,"given":"Eriko","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"10","key":"R1","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s00520-004-0662-x","article-title":"Chemotherapy-induced nausea and vomiting in routine practice: a European perspective","volume":"12","author":"Glaus","journal-title":"Support Care Cancer"},{"issue":"12","key":"R2","doi-asserted-by":"publisher","first-page":"e2288","DOI":"10.1002\/onco.13978","article-title":"Quality of life associated with nausea and vomiting from anthracycline-based chemotherapy: a pooled data analysis from three prospective trials","volume":"26","author":"Yeo","journal-title":"Oncologist"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.11.002","article-title":"A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"54","author":"Clemons","journal-title":"The Breast"},{"key":"R4","unstructured":"NCCN clinical practice guidelines in oncology (NCCN guidelines): Antiemetics. version 2.2025. National Comprehensive Cancer Network. URL: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category= 3&id=1415 [Accessed 20-01-2026]"},{"issue":"2","key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","journal-title":"ESMO Open"},{"issue":"24","key":"R6","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO Guideline Update","volume":"38","author":"Hesketh","journal-title":"J Clin Oncol"},{"issue":"7","key":"R7","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","article-title":"2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis","volume":"29","author":"Iihara","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"R8","doi-asserted-by":"publisher","DOI":"10.15761\/JTS.1000300","article-title":"A possible role for ghrelinergic stimulation through blockade of 5-HT2B\/5-HT2C receptors in antiemetic action of olanzapine","volume":"5","author":"Y","journal-title":"J Transl Sci"},{"issue":"2","key":"R9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","journal-title":"Lancet Oncol"},{"issue":"2","key":"R10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","article-title":"A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy","volume":"23","author":"Yanai","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"R11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/jjco\/hyx084","article-title":"A phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy","volume":"47","author":"Nakashima","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"R12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00520-015-2829-z","article-title":"Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial","volume":"24","author":"Abe","journal-title":"Support Care Cancer"},{"issue":"1","key":"R13","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-131","article-title":"Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting","volume":"28","author":"Tan","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"R14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1470-2045(23)00628-9","article-title":"Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial","volume":"25","author":"Bajpai","journal-title":"Lancet Oncol"},{"issue":"2","key":"R15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.21.01315","article-title":"Randomized, double-blind, phase iii study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE","volume":"40","author":"Hata","journal-title":"JCO"},{"issue":"8","key":"R16","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/cncr.34088","article-title":"A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE\u2010BC","volume":"128","author":"Matsuura","journal-title":"Cancer"},{"issue":"5","key":"R17","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s12325-023-02474-5","article-title":"Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting: a short review and clinical perspective","volume":"40","author":"Abe","journal-title":"Adv Ther"},{"issue":"9","key":"R18","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","journal-title":"AJP"},{"issue":"5","key":"R19","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","article-title":"Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan","volume":"20","author":"Tamura","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"R20","doi-asserted-by":"publisher","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"106","author":"Basch","journal-title":"JNCI Journal of the National Cancer Institute"},{"issue":"7","key":"R21","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1002\/cam4.1560","article-title":"Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy","volume":"7","author":"Navari","journal-title":"Cancer Med"},{"issue":"4","key":"R22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/00002820-199708000-00005","article-title":"Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale","volume":"20","author":"B\u00f6rjeson","journal-title":"Cancer Nurs"},{"issue":"27","key":"R23","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","journal-title":"JCO"},{"issue":"3","key":"R24","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1634\/theoncologist.2019-0527","article-title":"Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy","volume":"25","author":"Schwartzberg","journal-title":"Oncologist"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.01.005","article-title":"A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients","volume":"50","author":"Yeo","journal-title":"The Breast"},{"key":"R26","unstructured":"Summary technical documentation for Arokaris (in Japanese) [Technical documentation describing the formulation, pharmacological background, and regulatory information of arokaris relevant to its clinical use]. PMDA. URL: https:\/\/www.pmda.go.jp\/drugs\/2022\/P20220325004\/index.html [Accessed 20-01-2026]"},{"issue":"2","key":"R27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","journal-title":"N Engl J Med"},{"issue":"6","key":"R28","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","article-title":"Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea?","volume":"20","author":"Ng","journal-title":"Oncologist"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e85648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:13:53Z","timestamp":1782839633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e85648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2196\/85648","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"v15i10e85648"}}